Abstract Details
|
Richard L. Yates
(Green-Templeton College)
PRESENTER |
No disclosure on file |
| Margaret Esiri | Margaret Esiri has stock in Cytox Group. |
| Jacqueline Palace (John Radcliff Hospital Oxford Univeristy Hospitals Trust) | Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono, Medimmune, Argenx, Janssen, AMgen, UCB, Roche, Novartis, Amplo, Alexion, . Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche, UCB, Alexion, Amgen. Dr. Palace has or had stock in Astra Zenica. The institution of Dr. Palace has received research support from Roche, AMPLO, Alexion, UCB,. argenx, amgen. Dr. Palace has received intellectual property interests from a discovery or technology relating to health care. |
| Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN (University of Oxford) | Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurology Academy. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wellcome Trust. The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from UK MS Society. The institution of Dr. De Luca has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. De Luca has received research support from US Department of Defense. The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from Rosetrees Trust. The institution of Dr. De Luca has received research support from Strategic Innovation Fund, Oxford University. The institution of Dr. De Luca has received research support from Agence National de la Recherche. Dr. De Luca has a non-compensated relationship as a Editorial board member with MS Journal that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Steering Group member with MS Academy that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Board of Directors with SEQUINS that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Editorial board member with Continuum (AAN) that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Editorial board member with Frontiers in Neurology that is relevant to AAN interests or activities. |